Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laia Fernandez-Mañas"'
Autor:
Laia Fernandez-Mañas, Laura Gonzalez Aguado, Caterina Aversa, Laura Ferrer-Mileo, Marta Garcia de Herreros, Natalia Jiménez, Albert Febrer, Roger Vernet, Samuel García-Esteve, Begona Mellado, Oscar Reig Torras
Publikováno v:
Journal of Clinical Oncology. 41:681-681
681 Background: Immune checkpoint inhibitors (ICI) are the standard of care for metastatic renal cell carcinoma (mRCC). Circadian rhythm drives organisms to properly predict and react to cyclical changes in the environment, and also affects the adapt
Autor:
Oscar Reig Torras, Natalia Jiménez, Marta Garcia de Herreros, Caterina Aversa, Mercedes Marin, Laura Ferrer, Leonardo Rodriguez-Carunchio, Isabel Trias, Laia Fernandez-Mañas, Samuel García-Esteve, Albert Font Pous, Alejo Rodriguez-Vida, Montserrat Domenech-Santasusana, Mariona Figols, Miguel Ángel Climent, Sara Cros Costa, Isabel Chirivella, Daniel Herrero Rivera, Cristina Suárez, Begoña Mellado-Gonzalez
Publikováno v:
Journal of Clinical Oncology. 41:236-236
236 Background: Alterations on the tumor suppressor genes (TSG) RB1, PTEN and TP53 are associated with treatment resistance and aggressive clinical evolution of prostate cancer patients (pts). We developed and assessed the role of a TSG gene expressi
Autor:
Lucio Ghiglione, Laia Fernandez-Mañas, Laura Ferrer-Mileo, Caterina Aversa, Marta Garcia de Herreros, Juan Carlos Laguna, Teresa Gorria, Mercedes Marin, Natalia Jiménez, Aleix Prat, Joan Maurel, Begona Mellado, Oscar Reig
Publikováno v:
Journal of Clinical Oncology. 40:e16515-e16515
e16515 Background: Combination therapy with ICI and anti-VEGF has become the standard first-line (1L) therapy for metastatic clear cell RCC (mccRCC). However, about 25% of patients (pts) are long responders to anti-VEGF monotherapy. PBRM1 genomic alt
Autor:
Ivan Archilla, Leire Pedrosa, Marta Garcia de Herreros, Laia Fernandez-Mañas, Francis Esposito, Pedro Jares, Carolina Figueras, Sandra López, Helena Oliveres, Carles Foguet, Marta Cascante, Joan Maurel, Miriam Cuatrecasas
Publikováno v:
Journal of Clinical Oncology. 40:e15534-e15534
e15534 Background: The overall response rate following immune check-point blockade (ICB) is < 5% in microsatellite stable (MSS) advanced colorectal cancer (mCRC), and between 30-35% in MSI mCRC. We here evaluate the relationship between our immune-me